IP Library Granted Patent US 8,871,198
Granted Patent B2
US 8,871,198 · App. 11/724,094 · Granted Oct 28, 2014

Methods related to wound healing

Inventors: Charlotte A Emig (Gibsonia, PA); Catherine J Trumpower (Pittsburgh, PA); Vivienne S Marshall (San Antonio, TX)
Assignee: Stemnion, Inc.
A61K35/50C12N2501/11C12N5/0605C12N5/0629A61K35/12C12N2502/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,871,198
App. No.
11/724,094
Granted
Oct 28, 2014
Kind
B2
Abstract

The invention is directed to methods for the treatment of wounds. Such methods utilize novel compositions, including but not limited to amnion-derived multipotent cells (herein referred to as AMP cells), conditioned media derived therefrom (herein referred to as amnion-derived cellular cytokine suspension or ACCS), cell lysates derived therefrom, cell products derived therefrom, each alone or in combination.

Claims (11)

1. A method for accelerating wound healing of a treated burn wound as compared to the healing rate of a non-treated burn wound in a patient in need thereof comprising treating the burn wound by topically administering to the patient's burn wound about 0.25-1.0×10 6 cultured amnion-derived epithelial cells, wherein the cultured amnion-derived epithelial cells are made by the method comprising the steps of

a) obtaining a placenta and isolating an amnion from the placenta,

b) enzymatically releasing amnion-derived epithelial cells from the amnion,

c) collecting the released amnion-derived epithelial cells, and

d) culturing the collected amnion-derived epithelial cells of step (c) in basal culture medium that is supplemented with human serum albumin and recombinant human EGF.

2. The method of claim 1 wherein the basal medium is IMDM.

3. The method of claim 2 wherein the IMDM is supplemented with 0.5% human serum albumin.

4. The method of claim 1 wherein the recombinant human EGF is at a concentration of 10 ng/mL of culture medium.

5. The method of claim 1 wherein the amnion-derived epithelial cells, the basal medium, and all medium supplements are free of xeno-contamination.

6. The method of claim 1 wherein the treatment increases tensile strength and breaking strength of the healing treated burn wound as compared to the tensile strength and breaking strength in a healing non-treated burn wound.

7. The method of claim 1 wherein the treatment reduces fibrosis and collagen contraction in a healing treated burn wound as compared to the fibrosis and collagen contraction in a healing non-treated burn wound.

Assignments (3)
CONFIRMATORY LICENSE Recorded Nov 18, 2019
From: NOVEOME BIOTHERAPEUTICS, INC.
To: THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY
Reel/Frame 051044/0587 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2008
From: STEMNION, LLC
To: STEMNION INC.
Reel/Frame 020539/0561 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2007
From: SMITH, CHARLOTTE A.; TRUMPOWER, CATHERINE J.; MARSHALL, VIVIENNE S.
To: STEMNION LLC
Reel/Frame 019165/0070 →
Continuity (6)
Continuation In Part 11392892 · Mar 29, 2006
Continuation In Part 11333849 · Jan 18, 2006
Provisional Application 60666949 · Mar 31, 2005
Provisional Application 60699257 · Jul 14, 2005
Provisional Application 60742067 · Dec 2, 2005
Related Publication 20070231297A1 · Oct 4, 2007